Updated sensitivities to heavy neutral leptons at the LHC far detectors and SHiP
Physical Review D · 17.04.2026 · 113 (7)
DOI: 10.1103/fyd4-gk83 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physical Review D, online erschienen am 17.04.2026. Verfasst von Zeren Simon Wang und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
In recent years, a number of experiments dedicated to searches for long-lived particles (LLPs) have been proposed or approved, or have entered operation. While the sensitivities of these experiments to various LLP scenarios have been extensively studied, key aspects—such as detector geometries, background estimates, and projected operational durations—for several facilities, including MATHUSLA, ANUBIS, and SHiP, have undergone significant updates. In this work, we implement the latest experimental designs in the Displaced Decay Counter tool for calculating detector acceptances and signal-event yields, and reevaluate their sensitivity reach to one of the most widely studied LLP scenarios, namely minimal heavy neutral leptons.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Wang, Z. S., & Zhang, Y. (2026). Updated sensitivities to heavy neutral leptons at the LHC far detectors and SHiP. Physical Review D, 113(7). https://doi.org/10.1103/fyd4-gk83
Vancouver
Wang ZS, Zhang Y. Updated sensitivities to heavy neutral leptons at the LHC far detectors and SHiP. Physical Review D. 2026;113(7). doi:10.1103/fyd4-gk83
BibTeX
@article{Wang2026,
author = {Wang, Zeren Simon and Zhang, Yu},
title = {Updated sensitivities to heavy neutral leptons at the LHC far detectors and SHiP},
journal = {Physical Review D},
year = {2026},
volume = {113},
number = {7},
doi = {10.1103/fyd4-gk83}
}
EUVIMED